US 10,646,553 B2Granted

Use of recombinant human calcineurin B subunit

AssigneeHaikou Qili Pharmaceutical Co., Ltd.

InventorsKesheng Han, Jian Fu, Zongwen Huang, Shuhong Tian, Lifang Han

Life of this patent

Estimating the term…

Abstract

Provided is a use of a recombinant human calcineurin B subunit (rhCNB) in the preparation of a medicine for killing and/or inhibiting the gastric cancer.

Claims9

Dependent claims

A method for treating a cancer in a subject, comprising administering recombinant human Calcineurin subunit B (rhCNB) to the subject, wherein the cancer is gastric cancer.

Dependencies are inferred from the claim text.

Facts

Application: 16/020,363Filed 27 Jun 2018 · continuation
Priority: CN 2015 1 102173530 Dec 2015
Published: US 2018/0311320 A11 Nov 2018
Granted: 12 May 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 38/465
Hydrolases: acting on ester bonds , e.g. lipases, ribonucleases
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/08
Medicinal preparations characterised by special physical form: solutions
A61P 35/04
Antineoplastic agents: specific for metastasis

Family

PCT/CN2016/110744Parent of this continuation · filed 19 Dec 2016
US 2018/0311320 A1Pre-grant publication · published 1 Nov 2018
US 10,646,553 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results